GlassScriptPhysician profile
Carey L Patton
NPI 1215185871
$93,728.01
in general payments reported to CMS, 2019-2025
68 companies · $2,836 in 2025
The $2,836 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $27K · 2022: $30K · 2023: $10K · 2024: $24K · 2025: $2,836.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $25K · Food and Beverage: $11K · Travel and Lodging: $709 · Education: $51.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $25,327.22 |
| Food and Beverage | $10,592.52 |
| Travel and Lodging | $709.43 |
| Education | $51.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $56,103.68 | 2021-2024 | |
| Allergan, INC. | $21,845.41 | 2021-2022 | |
| Abbvie INC. | $3,063.04 | 2021-2025 | |
| Novo Nordisk INC | $1,274.30 | 2021-2025 | Wegovy, Saxenda, Rybelsus |
| Antares Pharma, INC. | $947.10 | 2021-2025 | Xyosted, Tlando, Nocdurna |
| Lilly USA, LLC | $722.58 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Corium, LLC | $658.23 | 2021-2025 | Azstarys |
| Bausch Health US, LLC | $541.28 | 2021-2025 | Aplenzin, Wellbutrin |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $521.84 | 2021-2025 | Xifaxan, Trulance, Ibschek |
| Amgen INC. | $511.05 | 2021-2025 | Repatha, Otezla, Repatha |
| Tris Pharma INC | $500.59 | 2022-2025 | Dyanavel Xr |
| Otsuka America Pharmaceutical, INC. | $384.33 | 2021-2025 | Rexulti |
| Axsome Therapeutics, INC. | $368.30 | 2023-2025 | Auvelity, Sunosi, Symbravo |
| Novartis Pharmaceuticals Corporation | $315.18 | 2021-2025 | |
| Ibsa Pharma INC. | $312.83 | 2023-2025 | Tirosint, Licart, Tirosint |
Show all 68 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $290.67 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Neos Therapeutics, LP | $288.22 | 2022-2024 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Pfizer INC. | $275.50 | 2021-2025 | |
| Ucb, INC. | $266.90 | 2024-2025 | Bimzelx |
| Biohaven Pharmaceuticals, INC. | $246.00 | 2021 | |
| Merck Sharp & Dohme LLC | $239.00 | 2021-2023 | Belsomra, Verquvo, Steglatro |
| Bayer Healthcare Pharmaceuticals INC. | $207.59 | 2021-2025 | |
| Qol Medical, LLC | $201.78 | 2022-2025 | Sucraid, Sucraid |
| Lundbeck LLC | $195.83 | 2024-2025 | Vyepti, Rexulti |
| Acerus Pharmaceuticals Corporation | $185.32 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $182.40 | 2022 | |
| Phathom Pharmaceuticals, INC. | $179.10 | 2024-2025 | Voquezna |
| Halozyme INC | $177.27 | 2023 | |
| Amarin Pharma, INC. | $164.07 | 2021-2022 | |
| Optinose US, INC. | $153.19 | 2021-2023 | |
| Corcept Therapeutics | $151.63 | 2021-2025 | Korlym |
| Shield Therapeutics INC | $146.17 | 2022-2025 | |
| Esperion Therapeutics, INC. | $144.03 | 2021-2025 | Nexletol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $143.32 | 2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $138.39 | 2021-2022 | |
| Eisai INC. | $126.95 | 2021 | |
| Currax Pharmaceuticals LLC | $111.01 | 2022-2024 | Nexletol, Contrave |
| Noven Therapeutics, LLC | $97.42 | 2024-2025 | Xelstrym |
| Sumitomo Pharma America, INC. | $91.70 | 2023-2025 | Gemtesa |
| Azurity Pharmaceuticals, INC. | $91.02 | 2024-2025 | Horizant, Edarbi, Azmiro |
| Verity Pharmaceuticals INC. | $89.70 | 2024-2025 | Tlando |
| Ironshore Pharmaceuticals INC. | $83.40 | 2022-2024 | |
| Cleerly, INC. | $82.35 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Rhythm Pharmaceuticals, INC. | $68.84 | 2024-2025 | Imcivree |
| Exact Sciences Corporation | $68.70 | 2024-2025 | Cologuard Collection Kit |
| Arbor Pharmaceuticals, INC. | $67.76 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $65.60 | 2021-2023 | Breztri |
| Amneal Pharmaceuticals LLC | $64.13 | 2022-2023 | Unithroid |
| Collegium Pharmaceutical, INC. | $63.63 | 2025 | Jornay Pm |
| Impel Pharmaceuticals INC. | $46.56 | 2023 | Trudhesa |
| Idorsia Pharmaceuticals US INC | $44.77 | 2022-2024 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $44.32 | 2021 | |
| Mayne Pharma Commercial LLC | $43.47 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $39.75 | 2021-2025 | Zoryve |
| Phadia US INC. | $37.77 | 2021 | |
| Astellas Pharma US INC | $35.49 | 2025 | Veozah |
| Janssen Pharmaceuticals, INC | $33.15 | 2021-2022 | |
| Ardelyx, INC. | $32.15 | 2024-2025 | Ibsrela |
| Endo Pharmaceuticals INC. | $31.67 | 2022-2023 | Nascobal |
| Aimmune Therapeutics, INC. | $19.07 | 2025 | Zenpep |
| Ironwood Pharmaceuticals, INC | $16.97 | 2024 | |
| Almatica Pharma LLC | $15.77 | 2023 | Loreev Xr, Gralise |
| Acella Pharmaceuticals, LLC | $15.72 | 2024 | NP Thyroid 60 |
| Dermavant Sciences, INC. | $15.05 | 2023 | Vtama |
| Adlon Therapeutics L.P. | $12.08 | 2021 | |
| Virtus Pharmaceuticals LLC | $12.06 | 2021 | |
| Therapeuticsmd, INC. | $11.41 | 2021 | |
| Organon LLC | $2.45 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carey Patton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.